Search results
Open Heart is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine. Research is published across all study phases and designs, from protocols to phase I trials to meta-analyses, including small or specialist studies.
Authors. Open Heart is an online-only open access journal dedicated exclusively to publishing cardiology research. The journal aims to provide rapid publication of research through a continuous publication model. As well as publishing definitive articles, Open Heart will consider protocols.
Access Open Heart's top cited articles. You will also find the journal's key metrics, including Impact Factor, Citescore, and lead times.
Open Heart is an online-only, open access cardiology journal that is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine.
Open Heart is a new international cardiovascular journal from BMJ and the British Cardiovascular Society, launching in January 2014. The journal will publish a broad range of cardiovascular articles, including research protocols/proposals, findings of translational research, observational studies, randomised trials, systematic reviews and meta ...
This publication focuses on the vital impact of wider multidisciplinary groups and should help define the generic core heart failure-specific competencies needed to support future pipelines of professionals, who regularly interact with and deliver care for patients with heart failure.
Cardiovascular disease is the leading cause of premature mortality in the developed world, and hypertension is its most important risk factor. Controlling hypertension is a major focus of public health initiatives, and dietary approaches have historically focused on sodium.
The advent of transcatheter mitral valve repair (TMVr) therapies has provided feasible and safe alternatives to medical and surgical treatment—especially for those patients who are not considered suitable candidates for conventional mitral valve surgery.
Future directions. The central paradigm in the treatment of CS is interrupting the self-perpetuating feedback loop of myocardial insult, worsening cardiac power, and further coronary and systemic perfusion mismatch in the context of increasingly maladaptive compensatory mechanisms (figure 1).
Measuring inactive forms of MGP, reflecting vitamin K deficiency, may ultimately prove useful in identifying individuals at increased risk of cardiac valve disease progression, and by extension, persons at greater risk of heart failure (HF) and CVD events.
